KA/EN
Register
Medicines reference
Search
Search
Product

Dalacin C Phosphate

Favourites

Clindamycin · Pfizer

2 forms: solution. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form Dose Frequency Georgia
150 mg/ml, Solution No label dose in the reference yet - Georgia Yes, human
In force until 11 May 2028
Human (Ministry of Health, RAMA)
In the register: დალაცინი C ფოსფატი 150 მგ/მლ, 2 მლ ამპულა, საინექციო ხსნარი
№ რ-038087
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Dalacin C Phosphate 150 mg/ml, Solution

2 ml ampoule, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis.
6.6/10
Situational / acceptable
vetman assessment

Dalacin C Phosphate

150 mg/ml, 2 ml ampoule, solution for injection, human medicine
Assessed clinical scopeDog · Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis. · IV,IM
Care settingHospital/clinic antimicrobial therapy with aseptic preparation, culture when indicated, controlled IV infusion or carefully selected IM use and monitoring
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038087 · Verified on 16 Oct 2026 Off-label use

A credible off-label hospital IV option for selected susceptible serious infections when oral therapy is unsuitable, but not a broad empirical rescue antibiotic. Dilute and infuse exactly as labelled; avoid routine IM use because canine studies show pain and muscle injury. Culture, source control and a planned step-down remain central.

Regulatory and scientific credibility8.0/10

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Clinical efficacy7.0/10

Two direct canine parenteral PK studies support systemic exposure; 11 mg/kg IV maintained concentrations above reported MICs for staphylococci and many anaerobes over the studied interval. Clinical outcome evidence is mostly from oral veterinary use, so susceptibility, infection site, source control and stewardship remain decisive; aerobic Gram-negative organisms, enterococci and CNS infection are not reliably covered.

Safety and tolerability5.0/10

The exact solution contains 9 mg/ml benzyl alcohol and requires dilution for IV use, a concentration no higher than 18 mg/ml and an infusion rate no faster than 30 mg/min; rapid or undiluted IV dosing is unsafe. Direct canine studies found IM pain and marked CPK elevation, with one phosphate study concluding IM could not be recommended. GI dysbiosis, hypersensitivity, renal/hepatic abnormalities and neuromuscular blockade remain relevant.

Clinical practicality6.5/10

The 2 ml ampoule contains 300 mg and is the less wasteful exact pack for small patients. It is ready for undiluted IM injection, but canine local-tolerance evidence argues against routine IM use. IV dosing needs aseptic withdrawal, compatible diluent, concentration/rate calculation, venous access and monitored infusion; opened single-use remainder is discarded.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never inject this concentrate as an undiluted IV bolus. Dilute to no more than 18 mg/ml and infuse at no more than 30 mg/min over the label-specified minimum time; monitor the catheter, circulation and patient during administration.
  • Avoid routine IM administration. Direct canine clindamycin-phosphate evidence found pain and muscle injury/marked CPK elevation; do not assume human-label IM permission establishes acceptable veterinary local tolerance.
  • This exact solution contains 9 mg/ml benzyl alcohol. Include all concurrent sources when estimating exposure and use added caution in neonates, small patients, prolonged/repeated courses, pregnancy, and hepatic or renal impairment; feline repeated-exposure safety is not established.
  • Confirm that the infection site and likely organism fit clindamycin; obtain cytology/culture and susceptibility for deep, recurrent, severe, previously treated or poorly responsive disease and reassess promptly. Inducible MLSB resistance can cause clinical failure.
  • Clindamycin does not reliably cover aerobic Gram-negative organisms, enterococci or protected CNS infection. Do not use this product as undifferentiated monotherapy for sepsis, urinary infection or meningitis; choose treatment from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or uncomplicated extraction and cannot replace radiographs, debridement, drainage or extraction. Reserve parenteral clindamycin for a clinically important infection with a justified route.
  • Vomiting or diarrhoea, dysbiosis and superinfection can occur even with parenteral therapy. Stop and reassess severe, persistent or bloody diarrhoea, systemic deterioration, hypersensitivity, jaundice or significant renal/hepatic laboratory change.
  • Clindamycin can enhance neuromuscular blockade; flag anaesthesia and neuromuscular-blocking drugs and monitor ventilation. Do not combine routinely with chloramphenicol or a macrolide because of possible ribosomal antagonism.
  • Do not mix in the same solution with listed incompatible drugs, including ceftriaxone, ampicillin, aminophylline, calcium gluconate, ciprofloxacin, phenytoin, magnesium sulfate or ranitidine. Verify Y-site and admixture compatibility from a current hospital source.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established for this exact benzyl-alcohol-containing parenteral product. Use only after individual benefit-risk assessment and select an alternative formulation when excipient exposure is avoidable.
Assessment sources
  1. Dalacin C Phosphate market audit2026
  2. Dalacin C Phosphate SmPC2026
  3. Antirobe veterinary SPC2025
  4. AAFP/AAHA stewardship2022
  5. ISCAID canine pyoderma2025
  6. AAHA dental guideline2019
  7. Canine clindamycin phosphate IV/IM PK1992
  8. Canine clindamycin parenteral PK1999
  9. Canine pyoderma RCT1999
  10. Canine/feline toxoplasmosis2000
  11. Feline IV clindamycin case2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis.
6.0/10
Situational / acceptable
vetman assessment

Dalacin C Phosphate

150 mg/ml, 2 ml ampoule, solution for injection, human medicine
Assessed clinical scopeCat · Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis. · IV,IM
Care settingHospital/clinic antimicrobial therapy with aseptic preparation, culture when indicated, controlled IV infusion or carefully selected IM use and monitoring
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, human · № რ-038087 · Verified on 16 Oct 2026 Off-label use

Clindamycin may be clinically justified in selected cats, but evidence for this exact parenteral human formulation and route is thin. Prefer a better-supported patient-appropriate route when feasible; if IV use is necessary, control dilution/rate and account for benzyl alcohol, interactions and monitoring. Routine IM use is not supported.

Regulatory and scientific credibility8.0/10

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Clinical efficacy5.5/10

Clindamycin has an established feline systemic role in susceptible wounds/oral infections and compatible toxoplasmosis, but direct controlled evidence for this IV/IM human phosphate formulation in cats is absent. Published IV use is largely case-level and cannot establish route-specific benefit; diagnosis, susceptibility and source control remain essential.

Safety and tolerability4.5/10

The exact solution contains 9 mg/ml benzyl alcohol, and feline safety for repeated exposure to this excipient/formulation is not established. Mandatory IV dilution and rate control, injection-site injury, GI dysbiosis, hypersensitivity and neuromuscular-blockade interactions remain relevant; direct feline IV/IM tolerability data are insufficient, so the safety margin is uncertain.

Clinical practicality6.0/10

The 2 ml ampoule contains 300 mg and is the less wasteful exact pack for small patients. It is ready for undiluted IM injection, but canine local-tolerance evidence argues against routine IM use. IV dosing needs aseptic withdrawal, compatible diluent, concentration/rate calculation, venous access and monitored infusion; opened single-use remainder is discarded.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never inject this concentrate as an undiluted IV bolus. Dilute to no more than 18 mg/ml and infuse at no more than 30 mg/min over the label-specified minimum time; monitor the catheter, circulation and patient during administration.
  • Avoid routine IM administration. Direct canine clindamycin-phosphate evidence found pain and muscle injury/marked CPK elevation; do not assume human-label IM permission establishes acceptable veterinary local tolerance.
  • This exact solution contains 9 mg/ml benzyl alcohol. Include all concurrent sources when estimating exposure and use added caution in neonates, small patients, prolonged/repeated courses, pregnancy, and hepatic or renal impairment; feline repeated-exposure safety is not established.
  • Confirm that the infection site and likely organism fit clindamycin; obtain cytology/culture and susceptibility for deep, recurrent, severe, previously treated or poorly responsive disease and reassess promptly. Inducible MLSB resistance can cause clinical failure.
  • Clindamycin does not reliably cover aerobic Gram-negative organisms, enterococci or protected CNS infection. Do not use this product as undifferentiated monotherapy for sepsis, urinary infection or meningitis; choose treatment from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or uncomplicated extraction and cannot replace radiographs, debridement, drainage or extraction. Reserve parenteral clindamycin for a clinically important infection with a justified route.
  • Vomiting or diarrhoea, dysbiosis and superinfection can occur even with parenteral therapy. Stop and reassess severe, persistent or bloody diarrhoea, systemic deterioration, hypersensitivity, jaundice or significant renal/hepatic laboratory change.
  • Clindamycin can enhance neuromuscular blockade; flag anaesthesia and neuromuscular-blocking drugs and monitor ventilation. Do not combine routinely with chloramphenicol or a macrolide because of possible ribosomal antagonism.
  • Do not mix in the same solution with listed incompatible drugs, including ceftriaxone, ampicillin, aminophylline, calcium gluconate, ciprofloxacin, phenytoin, magnesium sulfate or ranitidine. Verify Y-site and admixture compatibility from a current hospital source.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established for this exact benzyl-alcohol-containing parenteral product. Use only after individual benefit-risk assessment and select an alternative formulation when excipient exposure is avoidable.
Assessment sources
  1. Dalacin C Phosphate market audit2026
  2. Dalacin C Phosphate SmPC2026
  3. Antirobe veterinary SPC2025
  4. AAFP/AAHA stewardship2022
  5. ISCAID canine pyoderma2025
  6. AAHA dental guideline2019
  7. Canine clindamycin phosphate IV/IM PK1992
  8. Canine clindamycin parenteral PK1999
  9. Canine pyoderma RCT1999
  10. Canine/feline toxoplasmosis2000
  11. Feline IV clindamycin case2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Clindamycin150 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular
Manufacturer
Pfizer · United States
Registration
Georgia Yes, human
In force until 11 May 2028
Human (Ministry of Health, RAMA)
In the register: დალაცინი C ფოსფატი 150 მგ/მლ, 2 მლ ამპულა, საინექციო ხსნარი
№ რ-038087
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL000570959
Verified on: 16 Oct 2026
 US Yes, human
№ ANDA062803, NDA050441
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
150 mg/ml, Solution No label dose in the reference yet - Georgia Yes, human
In force until 11 May 2028
Human (Ministry of Health, RAMA)
In the register: დალაცინი C ფოსფატი 150 მგ/მლ, 4 მლ ამპულა, საინექციო ხსნარი
№ რ-038088
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Dalacin C Phosphate 150 mg/ml, Solution

4 ml ampoule, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis.
6.5/10
Situational / acceptable
vetman assessment

Dalacin C Phosphate

150 mg/ml, 4 ml ampoule, solution for injection, human medicine
Assessed clinical scopeDog · Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis. · IV,IM
Care settingHospital/clinic antimicrobial therapy with aseptic preparation, culture when indicated, controlled IV infusion or carefully selected IM use and monitoring
vetman score 6.5/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038088 · Verified on 16 Oct 2026 Off-label use

A credible off-label hospital IV option for selected susceptible serious infections when oral therapy is unsuitable, but not a broad empirical rescue antibiotic. Dilute and infuse exactly as labelled; avoid routine IM use because canine studies show pain and muscle injury. Culture, source control and a planned step-down remain central.

Regulatory and scientific credibility8.0/10

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Clinical efficacy7.0/10

Two direct canine parenteral PK studies support systemic exposure; 11 mg/kg IV maintained concentrations above reported MICs for staphylococci and many anaerobes over the studied interval. Clinical outcome evidence is mostly from oral veterinary use, so susceptibility, infection site, source control and stewardship remain decisive; aerobic Gram-negative organisms, enterococci and CNS infection are not reliably covered.

Safety and tolerability5.0/10

The exact solution contains 9 mg/ml benzyl alcohol and requires dilution for IV use, a concentration no higher than 18 mg/ml and an infusion rate no faster than 30 mg/min; rapid or undiluted IV dosing is unsafe. Direct canine studies found IM pain and marked CPK elevation, with one phosphate study concluding IM could not be recommended. GI dysbiosis, hypersensitivity, renal/hepatic abnormalities and neuromuscular blockade remain relevant.

Clinical practicality5.5/10

The 4 ml ampoule contains 600 mg and can reduce ampoule count for a large dog or high hospital dose, but creates substantial waste for cats and small dogs. IV use requires aseptic dilution, concentration/rate calculation, venous access and monitored infusion; IM delivery of large volumes is painful and poorly supported, and opened remainder is discarded.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never inject this concentrate as an undiluted IV bolus. Dilute to no more than 18 mg/ml and infuse at no more than 30 mg/min over the label-specified minimum time; monitor the catheter, circulation and patient during administration.
  • Avoid routine IM administration. Direct canine clindamycin-phosphate evidence found pain and muscle injury/marked CPK elevation; do not assume human-label IM permission establishes acceptable veterinary local tolerance.
  • This exact solution contains 9 mg/ml benzyl alcohol. Include all concurrent sources when estimating exposure and use added caution in neonates, small patients, prolonged/repeated courses, pregnancy, and hepatic or renal impairment; feline repeated-exposure safety is not established.
  • Confirm that the infection site and likely organism fit clindamycin; obtain cytology/culture and susceptibility for deep, recurrent, severe, previously treated or poorly responsive disease and reassess promptly. Inducible MLSB resistance can cause clinical failure.
  • Clindamycin does not reliably cover aerobic Gram-negative organisms, enterococci or protected CNS infection. Do not use this product as undifferentiated monotherapy for sepsis, urinary infection or meningitis; choose treatment from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or uncomplicated extraction and cannot replace radiographs, debridement, drainage or extraction. Reserve parenteral clindamycin for a clinically important infection with a justified route.
  • Vomiting or diarrhoea, dysbiosis and superinfection can occur even with parenteral therapy. Stop and reassess severe, persistent or bloody diarrhoea, systemic deterioration, hypersensitivity, jaundice or significant renal/hepatic laboratory change.
  • Clindamycin can enhance neuromuscular blockade; flag anaesthesia and neuromuscular-blocking drugs and monitor ventilation. Do not combine routinely with chloramphenicol or a macrolide because of possible ribosomal antagonism.
  • Do not mix in the same solution with listed incompatible drugs, including ceftriaxone, ampicillin, aminophylline, calcium gluconate, ciprofloxacin, phenytoin, magnesium sulfate or ranitidine. Verify Y-site and admixture compatibility from a current hospital source.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established for this exact benzyl-alcohol-containing parenteral product. Use only after individual benefit-risk assessment and select an alternative formulation when excipient exposure is avoidable.
Assessment sources
  1. Dalacin C Phosphate market audit2026
  2. Dalacin C Phosphate SmPC2026
  3. Antirobe veterinary SPC2025
  4. AAFP/AAHA stewardship2022
  5. ISCAID canine pyoderma2025
  6. AAHA dental guideline2019
  7. Canine clindamycin phosphate IV/IM PK1992
  8. Canine clindamycin parenteral PK1999
  9. Canine pyoderma RCT1999
  10. Canine/feline toxoplasmosis2000
  11. Feline IV clindamycin case2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis.
5.8/10
Weak evidence support
vetman assessment

Dalacin C Phosphate

150 mg/ml, 4 ml ampoule, solution for injection, human medicine
Assessed clinical scopeCat · Serious susceptible Gram-positive or anaerobic infection requiring parenteral therapy after sampling and source control; not empiric Gram-negative coverage, meningitis or routine dental prophylaxis. · IV,IM
Care settingHospital/clinic antimicrobial therapy with aseptic preparation, culture when indicated, controlled IV infusion or carefully selected IM use and monitoring
vetman score 5.8/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-038088 · Verified on 16 Oct 2026 Off-label use

Clindamycin may be clinically justified in selected cats, but evidence for this exact parenteral human formulation and route is thin. Prefer a better-supported patient-appropriate route when feasible; if IV use is necessary, control dilution/rate and account for benzyl alcohol, interactions and monitoring. Routine IM use is not supported.

Regulatory and scientific credibility8.0/10

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Clinical efficacy5.5/10

Clindamycin has an established feline systemic role in susceptible wounds/oral infections and compatible toxoplasmosis, but direct controlled evidence for this IV/IM human phosphate formulation in cats is absent. Published IV use is largely case-level and cannot establish route-specific benefit; diagnosis, susceptibility and source control remain essential.

Safety and tolerability4.5/10

The exact solution contains 9 mg/ml benzyl alcohol, and feline safety for repeated exposure to this excipient/formulation is not established. Mandatory IV dilution and rate control, injection-site injury, GI dysbiosis, hypersensitivity and neuromuscular-blockade interactions remain relevant; direct feline IV/IM tolerability data are insufficient, so the safety margin is uncertain.

Clinical practicality5.0/10

The 4 ml ampoule contains 600 mg and can reduce ampoule count for a large dog or high hospital dose, but creates substantial waste for cats and small dogs. IV use requires aseptic dilution, concentration/rate calculation, venous access and monitored infusion; IM delivery of large volumes is painful and poorly supported, and opened remainder is discarded.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never inject this concentrate as an undiluted IV bolus. Dilute to no more than 18 mg/ml and infuse at no more than 30 mg/min over the label-specified minimum time; monitor the catheter, circulation and patient during administration.
  • Avoid routine IM administration. Direct canine clindamycin-phosphate evidence found pain and muscle injury/marked CPK elevation; do not assume human-label IM permission establishes acceptable veterinary local tolerance.
  • This exact solution contains 9 mg/ml benzyl alcohol. Include all concurrent sources when estimating exposure and use added caution in neonates, small patients, prolonged/repeated courses, pregnancy, and hepatic or renal impairment; feline repeated-exposure safety is not established.
  • Confirm that the infection site and likely organism fit clindamycin; obtain cytology/culture and susceptibility for deep, recurrent, severe, previously treated or poorly responsive disease and reassess promptly. Inducible MLSB resistance can cause clinical failure.
  • Clindamycin does not reliably cover aerobic Gram-negative organisms, enterococci or protected CNS infection. Do not use this product as undifferentiated monotherapy for sepsis, urinary infection or meningitis; choose treatment from the syndrome, sample and susceptibility.
  • Systemic antibiotics are usually not indicated for routine dental cleaning or uncomplicated extraction and cannot replace radiographs, debridement, drainage or extraction. Reserve parenteral clindamycin for a clinically important infection with a justified route.
  • Vomiting or diarrhoea, dysbiosis and superinfection can occur even with parenteral therapy. Stop and reassess severe, persistent or bloody diarrhoea, systemic deterioration, hypersensitivity, jaundice or significant renal/hepatic laboratory change.
  • Clindamycin can enhance neuromuscular blockade; flag anaesthesia and neuromuscular-blocking drugs and monitor ventilation. Do not combine routinely with chloramphenicol or a macrolide because of possible ribosomal antagonism.
  • Do not mix in the same solution with listed incompatible drugs, including ceftriaxone, ampicillin, aminophylline, calcium gluconate, ciprofloxacin, phenytoin, magnesium sulfate or ranitidine. Verify Y-site and admixture compatibility from a current hospital source.
  • Safety in pregnant or lactating bitches/queens and breeding animals is not established for this exact benzyl-alcohol-containing parenteral product. Use only after individual benefit-risk assessment and select an alternative formulation when excipient exposure is avoidable.
Assessment sources
  1. Dalacin C Phosphate market audit2026
  2. Dalacin C Phosphate SmPC2026
  3. Antirobe veterinary SPC2025
  4. AAFP/AAHA stewardship2022
  5. ISCAID canine pyoderma2025
  6. AAHA dental guideline2019
  7. Canine clindamycin phosphate IV/IM PK1992
  8. Canine clindamycin parenteral PK1999
  9. Canine pyoderma RCT1999
  10. Canine/feline toxoplasmosis2000
  11. Feline IV clindamycin case2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Clindamycin150 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular
Manufacturer
Pfizer · United States
Registration
Georgia Yes, human
In force until 11 May 2028
Human (Ministry of Health, RAMA)
In the register: დალაცინი C ფოსფატი 150 მგ/მლ, 4 მლ ამპულა, საინექციო ხსნარი
№ რ-038088
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL000570959
Verified on: 16 Oct 2026
 US Yes, human
№ ANDA062803, NDA050441
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Clindamycin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
5.5 mg/kg Dog, Cat Bacterial Infection By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clinacin 300 mg Tablets for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clindaseptin 25 mg/ml Oral Solution for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
11 mg/kg Dog, Cat Bacterial Infection; Skin and Soft Tissue Infection By mouth once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clindaseptin 25 mg/ml Oral Solution for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clinacin 300 mg Tablets for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
11 mg/kg Dog Osteomyelitis By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Clinacin 300 mg Tablets for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
5.5–33 mg/kg Dog Bacterial Infection By mouth 2 times daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Antirobe (clindamycin hydrochloride) capsules and Aquadrops oral solution - FDA label
FDA / DailyMed, 2026
11–33 mg/kg Dog Osteomyelitis By mouth 2 times daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Antirobe (clindamycin hydrochloride) capsules and Aquadrops oral solution - FDA label
FDA / DailyMed, 2026
11–33 mg/kg Cat Bacterial Infection By mouth once daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Antirobe (clindamycin hydrochloride) capsules and Aquadrops oral solution - FDA label
FDA / DailyMed, 2026

Known Contraindications

  • Critical
    Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations.
    Sources: VMD SPC · VMD
  • Warning
    ingestion of clindamycin by these species may cause severe gastro-intestinal disorders, that can sometimes be fatal.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗